Skip to main content
OpenTrials
Completed

NCT Number: NCT07194720

Effects of the Cornelian Cherry Supplementation on the Selected Physiological Parameters in Marathon Runners

Growing body of evidence indicates favorable effects of Cornus mas (Cornelian cherry) supplements on cardiometabolic risk, including the improvement of HDL and glycemic indices, in line with vascular benefits. Experimental data feature bioactives from Cornelian cherry as potential modulators of vascular function and blood pressure, plausibly via endothelial nitric oxide-related pathways, with possible downstream effects on autonomic reflex control; nevertheless, such links in humans remain poorly explored to date, especially in terms of endurance training and hypoxia tolerance.

In this cross-over, placebo-controlled study, a group of healthy amateur long-distance runners underwent two stages of a four-week dietary intervention (separated by four weeks of washout period), receiving Cornelian cherry lyophilisate or placebo. Each supplementation stage was accompanied by the comprehensive evaluation of the cardio-respiratory parameters and endothelial function.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

45 year–75 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Wroclaw Medical University

Wroclaw, Lower Silesian Voivodeship, 50-376, Poland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age above 45 years

Exclusion criteria

  • chronic disease of the nervous, cardiovascular or respiratory system
  • disease of the digestive system, including history of the intestinal surgery, inflammatory bowel disease, celiac disease, lactose intolerance and other malabsorption disorders
  • blood pressure-lowering treatment within the past year
  • tobacco smoking within the past year
  • antibiotic/probiotic treatment and laxative/prokinetic usage in three months preceding the anticipated enrollment

Treatment and study plan

Cornus mas lyophilisate

Dietary Supplement

Participants receiving a Cornus mas (Cornelian cherry) lyophilisate for 4 weeks.

Placebo

Dietary Supplement

Participants receiving a starch- and sugar-based placebo for 4 weeks.

Primary outcomes

  1. Systemic vascular resistance

    Time frame: From the beginning to the end of a supplementation period at 4 weeks.

    Resting systemic vascular resistance, evaluated non-invasively with a finger cuff-based device.

  2. Office blood pressure values (mean, systolic, diastolic)

    Time frame: From the beginning to the end of a supplementation period at 4 weeks.

    Resting arterial blood pressure values (mean, systolic, diastolic), measured continuously with a non-invasive, finger cuff-based device.

Secondary outcomes

  1. Peripheral chemoreflex sensitivity

    Time frame: From the beginning to the end of a supplementation period at 4 weeks.

    Peripheral chemoreflex sensitivity, measured with the transient hypoxia test.

  2. eNOS expression

    Time frame: From the beginning to the end of a supplementation period at 4 weeks.

    Endothelial nitric oxide synthase expression, evaluated in the peripheral blood samples.

Sponsors and collaborators

Lead sponsor

Wroclaw Medical University

Other

Collaborators

  • Wroclaw University of Environmental and Life Sciences

Registry information

Official study title

Effects of the Cornelian Cherry (Cornus Mas L.) Lyophilisate Supplementation on the Selected Physiological Parameters in Amateur Long-Distance Runners

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Sep 26, 2025
Registry last updated
Oct 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.